Search

Your search keyword '"Jacinda B. Sampson"' showing total 88 results

Search Constraints

Start Over You searched for: Author "Jacinda B. Sampson" Remove constraint Author: "Jacinda B. Sampson"
88 results on '"Jacinda B. Sampson"'

Search Results

1. Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy

2. Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019

3. Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation

6. Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1

7. Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11

8. A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder

9. Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain

10. Dominant and recessive congenital myasthenic syndromes caused by SYT2 mutations

11. Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases

12. A concurrent dual analysis of genomic data augments diagnoses: Experiences of 2 clinical sites in the Undiagnosed Diseases Network

13. One is the loneliest number: genotypic matchmaking using the electronic health record

14. Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science

15. Nusinersen Treatment in Adults With Spinal Muscular Atrophy

16. Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder

17. De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation

18. Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2

19. Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019

20. Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation

21. Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy

22. Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification

23. Expanding the Spectrum of BAF-Related Disorders: De Novo Variants in SMARCC2 Cause a Syndrome with Intellectual Disability and Developmental Delay

24. An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

25. Advances in the Therapy of Spinal Muscular Atrophy

26. DEFINING THE DIVERSITY OF HNRNPA1 MUTATIONS IN CLINICAL PHENOTYPE AND PATHOMECHANISM

27. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

28. Diagnosis of Myotonic Dystrophy Based on Resting State fMRI Using Convolutional Neural Networks

29. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy

30. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor beta Signaling

31. FGFR3 Antibodies in Neuropathy: What to Do With Them?

32. C-terminal proline deletions in KCNC3 cause delayed channel inactivation and an adult-onset progressive SCA13 with spasticity

33. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening

34. Correction to: An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

35. Correction: Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

36. A variant of uncertain significance in SDHAF1, the succinate dehydrogenase chaperone protein, in an adult patient with spastic paraparesis and leukoencephalopathy

37. A 31-Year-Old Man With a Ring-Enhancing Brain Lesion

38. Connexin43 Mutant Patient-Derived Induced Pluripotent Stem Cells Exhibit Altered Differentiation Potential

39. Minimally Invasive Thymectomy and Lung Volume Reduction in a Patient With Myasthenia Gravis

40. Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)

41. De Novo Pathogenic Variants in N-cadherin Cause a Syndromic Neurodevelopmental Disorder with Corpus Callosum, Axon, Cardiac, Ocular, and Genital Defects

42. Connexin43 is Dispensable for Early Stage Human Mesenchymal Stem Cell Adipogenic Differentiation But is Protective against Cell Senescence

43. De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas, Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia

44. Specific functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia

45. Consensus-based care recommendations for adults with myotonic dystrophy type 1

46. Dynamic regulation of connexins in stem cell pluripotency

47. IRF2BPL Is Associated with Neurological Phenotypes

48. A Comprehensive Iterative Approach is Highly Effective in Diagnosing Individuals who are Exome Negative

49. Manipulating Cx43 expression triggers gene reprogramming events in dermal fibroblasts from oculodentodigital dysplasia patients

50. A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis

Catalog

Books, media, physical & digital resources